Mohsen Sohi Sells 4,058 Shares of STERIS (NYSE:STE) Stock

STERIS plc (NYSE:STE) Director Mohsen Sohi sold 4,058 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $235.78, for a total value of $956,795.24. Following the completion of the sale, the director directly owned 24,305 shares of the company’s stock, valued at approximately $5,730,632.90. This trade represents a 14.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

STERIS Price Performance

Shares of NYSE STE opened at $236.00 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.35 and a current ratio of 1.91. STERIS plc has a one year low of $195.14 and a one year high of $269.44. The firm has a market capitalization of $23.01 billion, a P/E ratio of 28.85 and a beta of 0.91. The company’s fifty day moving average is $216.98 and its two-hundred day moving average is $224.54.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.49 by $0.10. STERIS had a net margin of 13.34% and a return on equity of 14.34%. The business had revenue of $1.49 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm posted $2.34 EPS. The business’s revenue was up 7.3% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Analysts forecast that STERIS plc will post 11.09 EPS for the current fiscal year.

STERIS Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Friday, September 4th will be issued a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a yield of 1.2%. This is a boost from STERIS’s previous quarterly dividend of $0.63. The ex-dividend date of this dividend is Friday, September 4th. STERIS’s dividend payout ratio is 30.81%.

Hedge Funds Weigh In On STERIS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STE. Dearborn Partners LLC purchased a new stake in shares of STERIS in the second quarter valued at about $23,392,000. Trust Co. of Vermont purchased a new position in shares of STERIS during the 2nd quarter worth approximately $41,000. Plato Investment Management Ltd purchased a new position in shares of STERIS during the 2nd quarter worth approximately $843,000. Stoneridge Investment Partners LLC acquired a new position in shares of STERIS during the 2nd quarter worth approximately $1,027,000. Finally, Generali Investments Management Co LLC acquired a new position in shares of STERIS during the 2nd quarter worth approximately $262,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. UBS Group decreased their price target on STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. KeyCorp dropped their price objective on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Piper Sandler reaffirmed an “overweight” rating and set a $275.00 price objective (up from $270.00) on shares of STERIS in a report on Friday, August 7th. Weiss Ratings downgraded STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. Finally, Wall Street Zen raised STERIS from a “hold” rating to a “buy” rating in a report on Sunday, August 9th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $271.33.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.